CSI Market
Sign In | Register

Vera Therapeutics Inc (VERA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VERA Annual Cash Flow →
Cash flow data covering Vera Therapeutics Inc–Jun 30 2025 offers a view into how Jun 30 2026's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-230.51
Depreciation & amortization0.27
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business0.00
Share-based Compensation29.07
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Convertible Notes Issuance Costs-
Gain Onissuance Of Convertible Notes-
Change In Fair Value Of Convertible Notes-
Impairment Loss On Property And Equipment And Intangible Asset-
Issuance Of Common Stock For Licensing Payment Net Of Costs-
Equity Securities Fv Ni Unrealized Gain Loss-
Increase Decrease In Operating Lease Liability-0.18
Operating Lease Payments-
Accretion Of Discount And Amortization Of Premium On Debt Securities Net-
Accretion Of Loan Exit Fee And Amortization Of Loan Costs Net-
Accretion Of Discount And Amortization Of Premium On Purchase Of Debt Securities-0.84
Upfront And Milestone Obligations Under License Agreements15.00
Operating Lease Right Of Use Asset Amortization Expense0.12
Income taxes0.00
Losses/ -gains on Investments net-0.25
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-7.30
Increase (Decrease) in Accrued Liabilities2.07
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets14.57
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-14.68
Discontinued operations0.00
Net Cash flow from Operating Activities-206.75
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities218.95
Payments to Acquire Marketable Securities-308.62
Real Estate Investments0.00
Proceeds From Sale Of Marketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-15.26
Discontinued operations0.00
Net Cash Flow from Investing Activities-104.96
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock5.86
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Finance Lease Principal Payments-
Proceeds From Issuance Of Series C Redeemable Convertible Preferred Stock-
Payment Of Issuance Costs Related To Issuance Of Redeemable Convertible Preferred Stock-
Proceeds From Borrowings Net Of Costs-
Payment Of Costs Related To Stock Offering-
Proceeds From Issuance Of Common Stock Follow On Offering-
Payments Of Stock Issuance Costs On Follow On Offering-
Proceeds From Short Swing Settlement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.86
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-206.78
Total Cash Flow-305.85
4 historic quarters locked

Sign in to unlock the full Vera Therapeutics Inc cash flow history.

Sign In Create Free Account

About Vera Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-342380

Figures are derived from filed reports and may be restated. Historical data is subject to revision.